Cancer chemotherapy and pharmacology

Keyphrases

Publications

volume 94, number 1, 2024

Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
Sashana Dixon, Ann Tenneil O'connor, Chloe Brooks-Noreiga, Michelle A Clark, Arkene Levy, Ana M Castejon
Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review. Cancer chemotherapy and pharmacology 94 (1) (2024)
Sashana Dixon, Ann Tenneil O'connor, Chloe Brooks-Noreiga, Michelle A Clark, Arkene Levy, Ana M Castejon
Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review. Cancer chemotherapy and pharmacology 94 (1) (2024)
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer chemotherapy and pharmacology 94 (1) (2024)
Atsushi Ogawa, Hiroshi Kawamoto, Junichi Hara, Atsushi Kikuta, Chitose Ogawa, Hiroaki Hiraga, Kenichi Yoshimura, Kazunari Miyairi, Reiko Omori, Tokihiro Ro, Yuna Kamei, Toshimi Kimura
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy. Cancer chemotherapy and pharmacology 94 (1) (2024)
Nancy H C Loos, Viët Bui, Daniëlle H de Jong, Maria C Lebre, Hilde Rosing, Jos H Beijnen, Alfred H Schinkel
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment. Cancer chemotherapy and pharmacology 94 (1) (2024)
Atsushi Ogawa, Hiroshi Kawamoto, Junichi Hara, Atsushi Kikuta, Chitose Ogawa, Hiroaki Hiraga, Kenichi Yoshimura, Kazunari Miyairi, Reiko Omori, Tokihiro Ro, Yuna Kamei, Toshimi Kimura
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy. Cancer chemotherapy and pharmacology 94 (1) (2024)
Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, Shoyo Shibata, Toshio Shimizu
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer chemotherapy and pharmacology 94 (1) (2024)
Vikram Malhi, Malgorzata Nowicka, Ya-Chi Chen, Priya Agarwal, Marie Waldvogel, Yi Ting Kayla Lien, Marc Hafner, Pablo Perez-Moreno, Heather M Moore, Jiajie Yu
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer chemotherapy and pharmacology 94 (1) (2024)
Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, Arun Prasath Raju, Mahadev Rao, Karthik S Udupa, Surulivel Rajan M
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients. Cancer chemotherapy and pharmacology 94 (1) (2024)
Vikram Malhi, Malgorzata Nowicka, Ya-Chi Chen, Priya Agarwal, Marie Waldvogel, Yi Ting Kayla Lien, Marc Hafner, Pablo Perez-Moreno, Heather M Moore, Jiajie Yu
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer chemotherapy and pharmacology 94 (1) (2024)
Wei Zheng, Wei Peng, Fuyong Qian, Mingshuai Zhang, Bofeng Duan, Zhifeng Fan, Yi Xie, Xiaoying Fu
Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
Vikram Malhi, Malgorzata Nowicka, Ya-Chi Chen, Priya Agarwal, Marie Waldvogel, Yi Ting Kayla Lien, Marc Hafner, Pablo Perez-Moreno, Heather M Moore, Jiajie Yu
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer chemotherapy and pharmacology 94 (1) (2024)
Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)
Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)
In Hee Lee, Soo Jung Lee, Juhyung Kim, Yoon Hee Lee, Gun Oh Chong, Jong Mi Kim, Juhun Lee, Nan Young Lee, Seo Young Park, Dea Gy Hong, Yee Soo Chae
Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
Wei Zheng, Wei Peng, Fuyong Qian, Mingshuai Zhang, Bofeng Duan, Zhifeng Fan, Yi Xie, Xiaoying Fu
Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
In Hee Lee, Soo Jung Lee, Juhyung Kim, Yoon Hee Lee, Gun Oh Chong, Jong Mi Kim, Juhun Lee, Nan Young Lee, Seo Young Park, Dea Gy Hong, Yee Soo Chae
Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, Arun Prasath Raju, Mahadev Rao, Karthik S Udupa, Surulivel Rajan M
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients. Cancer chemotherapy and pharmacology 94 (1) (2024)
Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, Shoyo Shibata, Toshio Shimizu
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)
Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, Shoyo Shibata, Toshio Shimizu
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)
Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data. Cancer chemotherapy and pharmacology 94 (1) (2024)
Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, Arun Prasath Raju, Mahadev Rao, Karthik S Udupa, Surulivel Rajan M
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients. Cancer chemotherapy and pharmacology 94 (1) (2024)
Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)
Atsushi Ogawa, Hiroshi Kawamoto, Junichi Hara, Atsushi Kikuta, Chitose Ogawa, Hiroaki Hiraga, Kenichi Yoshimura, Kazunari Miyairi, Reiko Omori, Tokihiro Ro, Yuna Kamei, Toshimi Kimura
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy. Cancer chemotherapy and pharmacology 94 (1) (2024)
Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology 94 (1) (2024)
Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, Shoyo Shibata, Toshio Shimizu
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology 94 (1) (2024)

volume 93, number 5, 2024

Marco Orleni, Jan H Beumer
Pharmacology and pharmacokinetics of tazemetostat. Cancer chemotherapy and pharmacology 93 (5) (2024)
Bin Fan, Ghassan K Abou-Alfa, Andrew X Zhu, Shuchi S Pandya, Hongxia Jia, Feng Yin, Camelia Gliser, Zhaowei Hua, Mohammad Hossain, Hua Yang
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study. Cancer chemotherapy and pharmacology 93 (5) (2024)
Bin Fan, Ghassan K Abou-Alfa, Andrew X Zhu, Shuchi S Pandya, Hongxia Jia, Feng Yin, Camelia Gliser, Zhaowei Hua, Mohammad Hossain, Hua Yang
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study. Cancer chemotherapy and pharmacology 93 (5) (2024)
Kadriye Bir Yücel, Uguray Aydos, Osman Sütçüoğlu, Atiye Cenay Karabörk Kilic, Nuriye Ozdemir, Ahmet Özet, Ozan Yazıcı
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors. Cancer chemotherapy and pharmacology 93 (5) (2024)
Marco Orleni, Jan H Beumer
Pharmacology and pharmacokinetics of tazemetostat. Cancer chemotherapy and pharmacology 93 (5) (2024)

volume 93, number 6, 2024

Yuchen Sun, Yue Cheng, Daniel Louis Hertz
Using maximum plasma concentration (C max ) to personalize taxane treatment and reduce toxicity. Cancer chemotherapy and pharmacology 93 (6) (2024)
Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Elisabeth Krogsgaard Petersen, Christina Harlev, Jakob Hansen, Thomas Baad-Hansen, Akmal Safwat, Maiken Stilling
Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study. Cancer chemotherapy and pharmacology 93 (6) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Alyssa Gaietto, John C Panetta, Jennifer L Pauley, Mary V Relling, Raul Ribeiro, Matthew J Ehrhardt, Ching-Hon Pui, Hiroto Inaba, Hope D Swanson
Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital. Cancer chemotherapy and pharmacology 93 (6) (2024)
Yuchen Sun, Yue Cheng, Daniel Louis Hertz
Using maximum plasma concentration (C max ) to personalize taxane treatment and reduce toxicity. Cancer chemotherapy and pharmacology 93 (6) (2024)
Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Elisabeth Krogsgaard Petersen, Christina Harlev, Jakob Hansen, Thomas Baad-Hansen, Akmal Safwat, Maiken Stilling
Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study. Cancer chemotherapy and pharmacology 93 (6) (2024)
Zhuoyuan Yu, Haifan Xu, Miao Feng, Liqun Chen
Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab. Cancer chemotherapy and pharmacology 93 (6) (2024)
John F Marcelletti, Branimir I Sikic
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype. Cancer chemotherapy and pharmacology 93 (6) (2024)
Xuan Ma, Zhenou Sun, Hui Chen, Lixing Cao, Shuang Zhao, Lihong Fan, Chong Zhao, Shutao Yin, Hongbo Hu
18β-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis. Cancer chemotherapy and pharmacology 93 (6) (2024)
Ahmed O ELKasar, Fatma Z Hussien, Hala E Abdel-Hamied, Ibrahim G Saleh, Elsayed M Mahgoup, Amr A El-Arabey, Adel R Abd-Allah
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study. Cancer chemotherapy and pharmacology 93 (6) (2024)
Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Elisabeth Krogsgaard Petersen, Christina Harlev, Jakob Hansen, Thomas Baad-Hansen, Akmal Safwat, Maiken Stilling
Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study. Cancer chemotherapy and pharmacology 93 (6) (2024)
Mayumi Ozawa, Jun Watanabe, Atsushi Ishibe, Koki Goto, Yoshiro Fujii, Kazuya Nakagawa, Yusuke Suwa, Hirokazu Suwa, Hidenobu Masui, Mitsutaka Sugita, Yasuhisa Mochizuki, Shigeru Yamagishi, Seiji Hasegawa, Yuki Homma, Masashi Momiyama, Takafumi Kumamoto, Ryusei Matsuyama, Kazuhisa Takeda, Masataka Taguri, Itaru Endo
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001). Cancer chemotherapy and pharmacology 93 (6) (2024)
Toshihiko Doi, Shunji Takahashi, Daisuke Aoki, Kan Yonemori, Hiroki Hara, Kosei Hasegawa, Kazuhiro Takehara, Kenichi Harano, Mayu Yunokawa, Hiroyuki Nomura, Tatsunori Shimoi, Koji Horie, Aiko Ogasawara, Shinichi Okame
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 93 (6) (2024)
Mayumi Ozawa, Jun Watanabe, Atsushi Ishibe, Koki Goto, Yoshiro Fujii, Kazuya Nakagawa, Yusuke Suwa, Hirokazu Suwa, Hidenobu Masui, Mitsutaka Sugita, Yasuhisa Mochizuki, Shigeru Yamagishi, Seiji Hasegawa, Yuki Homma, Masashi Momiyama, Takafumi Kumamoto, Ryusei Matsuyama, Kazuhisa Takeda, Masataka Taguri, Itaru Endo
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001). Cancer chemotherapy and pharmacology 93 (6) (2024)